scispace - formally typeset
M

Marco Canepa

Researcher at University of Genoa

Publications -  153
Citations -  3049

Marco Canepa is an academic researcher from University of Genoa. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 26, co-authored 110 publications receiving 2060 citations. Previous affiliations of Marco Canepa include Johns Hopkins University & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Impact of central obesity on the estimation of carotid-femoral pulse wave velocity.

TL;DR: When TD is measured over the body surface, the role of obesity on PWV is substantially overestimated, and after accounting for this bias, PWV was still independently associated with visceral fat but not with other measures of adiposity, confirming its contribution to arterial stiffening.
Journal ArticleDOI

Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry.

TL;DR: Evolving HCM populations include progressively greater representation of older patients with sporadic disease, mild phenotypes, and genotype-negative status, which suggests a prominent role of imaging over genetic testing in promoting HCM diagnoses and urges efforts to understand genotypes-negative disease eluding the classic monogenic paradigm.
Journal ArticleDOI

5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1.

TL;DR: The effect of 5FU on endothelial senescence and whether GLP‐1 antagonizes it is studied and it is shown that 5.5‐fluorouracil and its prodrug, capecitabine, can damage endothelial cells, whilst endothelial integrity is preserved by glucagon‐like peptide 1.
Journal ArticleDOI

Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials.

TL;DR: Very short DAPT did not increase the odds of ischemic complications, while reducing thedds of major or any bleeding by over 30%, and subgroup analyses showed consistent results for 1 versus 3 month DAPt and for aspirin versus P2Y12 inhibitor monotherapy following very short D APT.
Journal ArticleDOI

Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation.

TL;DR: Prevalence and incidence rate of AEs was high in a large, multicentric, real-world cohort of cardiac amyloidosis, and a consistent proportion of events occurred despite anticoagulation therapy or in patients in sinus rhythm.